Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Seliforant - Sensorion

Drug Profile

Seliforant - Sensorion

Alternative Names: SENS-111; UR-63325

Latest Information Update: 12 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Palau Pharma
  • Developer Palau Pharma; Sensorion
  • Class Antiallergics; Antiasthmatics; Antihistamines; Azetidines; Pyrimidines; Small molecules; Vestibular disorder therapies
  • Mechanism of Action Histamine H4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Vertigo
  • No development reported Asthma; Seasonal allergic rhinitis; Tinnitus

Most Recent Events

  • 23 Oct 2019 Sensorion terminates phase II trial in vertigo in Spain (EudraCT2016-003927-45)
  • 17 Oct 2019 Sensorion completes enrolment and treatment of 105 patients in phase II (SENS-111-201) trial for Vertigo
  • 17 May 2019 Seliforant is still in phase I trial for Vertigo in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top